Genocea Biosciences, which develops novel vaccines for infectious diseases through T cell immune responses, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $72 million by offering 5.5 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Genocea Biosciences would command a market value of $224 million.
Genocea Biosciences, which was founded in 2006 and booked $1 million in grant revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol GNCA. Genocea Biosciences initially filed confidentially on October 22, 2013. Citi and Cowen & Company are the joint bookrunners on the deal.
